EGI
ATRS

EAM Global Investors’s Antares Pharma, Inc. ATRS Stock Holding History

EAM Global Investors’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-542,145
Closed -$2.55M – 145
2019
Q4 		$2.55M Buy
+542,145
New +$2.22M 1.02% 25

Other funds holding ATRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

EAM Global Investors's ATRS Position: Q1 2020 in Review

EAM Global Investors sold out of Antares Pharma, Inc. (ATRS) in Q1 2020, closing a stake of 542,145 shares — an estimated $2.55M sold.

EAM Global Investors first reported a position in ATRS in Q4 2019 and held it in 1 quarter. The position peaked at $2.55M in Q4 2019. 154 funds tracked by Wall St. Rank hold ATRS as of Q1 2020.

  • EAM Global Investors reported no remaining Antares Pharma, Inc. position as of Q1 2020 after selling out during the quarter.
  • EAM Global Investors sold 542,145 Antares Pharma, Inc. shares in Q1 2020, an estimated $2.55M.
  • EAM Global Investors first reported a position in Antares Pharma, Inc. in Q4 2019 and held it in 1 quarter.
  • EAM Global Investors's Antares Pharma, Inc. position peaked at $2.55M in Q4 2019.
  • 154 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q1 2020.

Based on EAM Global Investors's 13F filing for Q1 2020, filed 13 May 2020.